Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibitor for Anti-Angiogenic Cancer Research

Executive Summary: Anlotinib hydrochloride is a small-molecule inhibitor targeting VEGFR2, PDGFRβ, and FGFR1 with high selectivity and nanomolar potency (Xie et al., 2018). The compound blocks angiogenesis and tumor growth by inhibiting receptor tyrosine kinase-mediated ERK signaling, as demonstrated in human endothelial cell and animal models (DOI). It exhibits superior efficacy compared to sunitinib and sorafenib in preclinical benchmarks. Oral bioavailability is high (28–77% depending on species), with a safety profile characterized by low systemic toxicity and minimal off-target effects. APExBIO supplies Anlotinib hydrochloride (SKU C8688), validated for robust, reproducible migration and tube formation assays (product link).

Biological Rationale

Angiogenesis, the formation of new blood vessels from pre-existing vasculature, is essential for tumor growth beyond 1 mm³ and is a hallmark of cancer progression (Xie et al., 2018). Vascular endothelial cells mediate this process via signaling through receptor tyrosine kinases, especially VEGFR2, PDGFRβ, and FGFR1. Inhibiting these pathways disrupts endothelial cell migration, proliferation, and capillary tube formation, limiting tumor vascularization and growth. Notably, targeting endothelial cells mitigates the rapid resistance seen in tumor cells due to their genetic stability. The high selectivity and potency of multi-target tyrosine kinase inhibitors such as Anlotinib hydrochloride make them valuable in dissecting angiogenic mechanisms and developing anti-cancer strategies (Related article—this article details updated benchmarking and workflow integration).

Mechanism of Action of Anlotinib hydrochloride

Anlotinib hydrochloride acts as a reversible, ATP-competitive inhibitor of VEGFR2, PDGFRβ, and FGFR1, with IC₅₀ values of 5.6 ± 1.2 nM, 8.7 ± 3.4 nM, and 11.7 ± 4.1 nM, respectively (human recombinant proteins, 25°C, pH 7.4) (Xie et al., 2018). By occupying the ATP-binding pocket, it blocks phosphorylation and downstream ERK pathway activation. This leads to concentration-dependent inhibition of endothelial cell migration, capillary-like tube formation, and microvessel sprouting in vitro. Anlotinib also reduces vascular density in tumor xenografts, confirming anti-angiogenic efficacy in vivo. The compound exhibits minimal cytotoxicity at concentrations up to 1 μM in EA.hy 926 endothelial cells, enabling use in functional assays without confounding cell death (APExBIO). A detailed comparison of mechanistic insight and translational relevance can be found in this resource—the current article updates pharmacokinetic and safety data for research planning.

Evidence & Benchmarks

• Anlotinib inhibits VEGF-induced phosphorylation of VEGFR2 in HUVECs with an IC₅₀ < 1 nM (Xie et al., 2018, DOI).
• In EA.hy 926 endothelial cells, migration and tube formation are inhibited in a concentration-dependent manner (IC₅₀ values: 5.6 ± 1.2 nM for VEGFR2, 8.7 ± 3.4 nM for PDGFRβ, 11.7 ± 4.1 nM for FGFR1) (Table 1).
• Superior anti-angiogenic activity is observed versus sunitinib, sorafenib, and nintedanib in standardized in vitro and in vivo assays (Xie et al., 2018).
• Oral bioavailability in rats (28–58%) and dogs (41–77%) is high, with rapid absorption and a terminal half-life of 5.1 ± 1.6 h (rat) and 22.8 ± 11.0 h (dog) (Pharmacokinetics).
• High plasma protein binding (93–97%) and extensive tissue distribution, including blood-brain barrier penetration, confirmed in preclinical models (Xie et al., 2018).
• Metabolized primarily by human CYP3A; in vitro CYP inhibition is observed, but clinical drug-drug interaction risk is low at research doses (Metabolism).
• Median lethal dose (LD₅₀) in 14-day oral rat studies: 1735.9 mg/kg; no significant liver, kidney, bone marrow, reproductive, or genetic toxicity at research-relevant concentrations (Toxicity).
• Validated for sensitive, reproducible endothelial migration and tube formation assays—see scenario guidance and protocol optimization in this article (this dossier provides updated quantitative IC₅₀ detail).

Applications, Limits & Misconceptions

Anlotinib hydrochloride (APExBIO C8688) is widely used in preclinical cancer biology to interrogate angiogenesis, receptor tyrosine kinase signaling, and tumor microenvironment dynamics. Its high selectivity and low cytotoxicity make it particularly suitable for mechanistic studies and high-content functional assays. The compound supports robust workflows in endothelial cell migration, capillary tube formation, and in vivo tumor xenograft models.

For deeper scenario-driven integration and troubleshooting, this article provides practical laboratory solutions; the current piece extends coverage with updated safety and pharmacokinetic benchmarks.

Common Pitfalls or Misconceptions

• Not a general cytotoxic agent: Anlotinib is not designed for direct tumor cell killing at research concentrations; anti-tumor effects are primarily via anti-angiogenesis (Xie et al., 2018).
• Limited effect on non-angiogenic tumors: Tumors that do not rely on neovascularization may not respond to VEGFR/PDGFR/FGFR inhibition (DOI).
• CYP3A interactions are low-risk in vitro: Although Anlotinib inhibits CYP3A4 in vitro, at standard research concentrations, drug-drug interactions are minimal (Metabolism).
• Species differences in PK: Pharmacokinetics may vary significantly between rats, dogs, and humans; dosing protocols must be adjusted accordingly (PK).
• Research use only: The product is not validated for clinical or diagnostic use (APExBIO).

Workflow Integration & Parameters

Anlotinib hydrochloride is supplied as a hydrochloride salt, stored at -20°C, and recommended for research use only by APExBIO (Anlotinib hydrochloride). For migration and tube formation assays, concentrations in the range of 1–100 nM are commonly used, with minimal cytotoxicity observed up to 1 μM. The compound dissolves readily in DMSO, and working solutions should be freshly prepared. Metabolic stability in vitro is maintained under standard cell culture conditions (37°C, 5% CO₂, pH 7.2–7.4). For in vivo studies, dosing regimens must consider species-specific absorption and clearance rates, as detailed above. Further guidance for advanced mechanistic and translational research design is available in this article; this dossier provides expanded, quantitative safety and PK detail.

Conclusion & Outlook

Anlotinib hydrochloride (APExBIO, SKU C8688) is a validated, potent multi-target tyrosine kinase inhibitor for anti-angiogenic research. Its exceptional selectivity, favorable pharmacokinetics, and low cytotoxicity support sensitive, reproducible studies in angiogenesis, migration, and signaling assays. Careful attention to experimental parameters and limitations ensures robust, interpretable results. Ongoing research continues to clarify its translational potential in cancer biology and drug development (Xie et al., 2018).